新しいβ受容体遮断薬，Ｂｏｐｉｎｄｏｌｏｌ及びその代謝産物のβ遮断作用と部分作用薬活性，膜安定化作用について

Abstract

The beta-blocking effects of bopindolol, a new long-acting beta-adrenoceptor antagonist, and its two metabolites, 18-502 and 20-785, were studied in the isolated atria and trachea preparations of the guinea pig. The partial agonist activity (PAA) and the membrane stabilizing activity (MSA) were studied in the pithed rat and the right ventricular papillary muscle preparations of the guinea pig, respectively. Antagonistic effect of bopindolol against isoproterenol was 1.1-2.8 and 14.1 times more potent than propranolol in the atria and the trachea preparations, respectively, while those of 18-502 were 34.7-38.0 (in atria) and 29.0 (in trachea) times more potent than propranolol. beta-Blocking potencies of 20-785 were 50% (in atria) and 10% (in trachea) of those of propranolol. Bopindolol, 18-502 and 20-785 increased the heart rate of the pithed rat dose-dependently. The effects were inhibited by pretreatment of the preparation with propranolol. The onset of action of bopindolol was slower and the duration, longer than those of its two metabolites. Bopindolol and 18-502 were more potent membrane stabilizers than propranolol, while 20-785 produced only a minimal stabilizing effect. These results indicate that not only bopindolol, but also the metabolites of bopindolol, 18-502 and 20-785 are potent beta-blocking agents with PAA. It is presumed that the long duration of action of bopindolol is due to the potent activities of its metabolites 18-502 and 20-785.